The Ministry of Food and Drug Safety (Director Oh Yu-kyung) announced on the 25th that it has approved Libtayo, a rare drug from Sanofi-Aventis Korea, for skin squamous cell cancer treatment. Libtayo is a monoclonal antibody targeting cell predetermined history 1 (PD-1)*, an immune gateway receptor for immune cells (T cells). Programmed cell death 1 (PD-1) is expressed in T cells, B cells, NK cells, and myeloid cells activated by inhibitory immune gate receptors belonging to the CD28 family, and plays a pivotal role in immune regulation. This drug blocks the mechanism of cancer cells avoiding immune cells (T cells) using PD-1, helping immune cells attack and remove cancer cells.

The Ministry of Food and